Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: Individual patient data-based meta-analysis of the German acute myeloid leukemia intergroup

Journal of Clinical Oncology

Volumn 27, Issue 18, 2009, Pages 3000-3006

  Krauter, Jürgen ^a   Wagner, Katharina ^a   Schäfer, Irina ^a   Marschalek, Rolf ^a   Meyer, Claus ^a   Heil, Gerhard ^a   Schaich, Markus ^a   Ehninger, Gerhard ^a   Niederwieser, Dietger ^a   Krahl, Rainer ^a   Büchner, Thomas ^a   Sauerland, Cristina ^a   Schlegelberger, Brigitte ^a   Döhner, Konstanze ^a   Döhner, Hartmut ^a   Schlenk, Richard F ^a   Ganser, Arnold ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME ABERRATION; CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RECIPROCAL CHROMOSOME TRANSLOCATION; TREATMENT RESPONSE; CHROMOSOME 11; GENE TRANSLOCATION; GENETICS; META ANALYSIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 11; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TRANSLOCATION, GENETIC;

EID: 67649992737     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.7981     Document Type: Article

References (37)

1. Super HJ, McCabe NR, Thirman MJ, et al: Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood 82:3705-3711, 1993
2. Bloomfield CD, Archer KJ, Mrozek K, et al: 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: Report from an international workshop. Genes Chromosomes Cancer 33:362-378, 2002
3. Strout MP, Marcucci G, Caligiuri MA, et al: Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: Biology and clinical implications. Ann Hematol 78:251-264, 1999
4. Meyer C, Schneider B, Jakob S, et al: The MLL recombinome of acute leukemias. Leukemia 20:777-784, 2006
5. Daser A, Rabbitts TH: Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis. Genes Dev 18:965-974, 2004
6. Cozzio A, Passegue E, Ayton PM, et al: Similar MLL-associated leukemias arising from selfrenewing stem cells and short-lived myeloid progenitors. Genes Dev 17:3029-3035, 2003
7. Corral J, Lavenir I, Impey H, et al: An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes. Cell 85:853-861, 1996
8. Krivtsov AV, Twomey D, Feng Z, et al: Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442:818-822, 2006
9. Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1612 patients entered into the MRC AML 10 trial. Blood 92:2322-2333, 1998
10. Byrd JC, Mrozek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336, 2002
11. Slovak ML, Kopecky KJ, Cassileth PA, et al: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloblastic leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 96:4075-4083, 2000
12. Mrozek K, Heinonen K, Lawrence D, et al: Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23: A Cancer and Leukemia Group B study. Blood 90:4532-4538, 1997
13. Martineau M, Berger R, Lillington DM, et al: The t(6;11)(q27;q23) translocation in acute leukemia: A laboratory and clinical study of 30 cases - EU Concerted Action 11q23 Workshop participants. Leukemia 12:788-791, 1998
14. Schlenk RF, Benner A, Hartmann F, et al: Risk-adapted postremission therapy in acute myeloid leukemia: Results of the German multicenter AML HD93 treatment trial. Leukemia 17:1521-1528, 2003
15. Schlenk RF, Döhner K, Pralle H, et al: Risk-adapted therapy in younger adults with acute myeloid leukemia: Results of the AMLHD98A trial of the AMLSG. Blood 108:8a, 2006 (suppl; abstr 14)
16. Heil G, Krauter J, Raghavachar A, et al: Risk-adapted induction and consolidation therapy in adults with de novo AML aged ≤ 60 years: Results of a prospective multicenter trial. Ann Hematol 83:336-344, 2004
17. Krauter J, Heil G, Hoelzer D, et al: Treatment of patients up to 60 years with high risk AML: Final results of the AML SHG-Hannover 01/99 trial. Blood 108:132a, 2006 (suppl; abstr 433)
18. Buchner T, Hiddemann W, Berdel WE, et al: 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): A randomized trial of the German AML Cooperative Group. J Clin Oncol 21:4496-4504, 2003
19. Buchner T, Berdel WE, Schoch C, et al: Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 24:2480-2489, 2006
20. Schaich M, Ritter M, Illmer T, et al: Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia. Br J Haematol 112:300-307, 2001
21. Meyer C, Schneider B, Reichel M, et al: Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. Proc Natl Acad Sci U S A 102:449-454, 2005
22. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003
23. Korn EL: Censoring distributions as a measure of follow-up in survival analysis. Stat Med 5:255-260, 1986
24. Andersen P, Gill RD: Cox's regression model for counting processes: A large sample study. Ann Stat 10:1100-1120, 1982
25. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
26. Rubnitz JE, Raimondi SC, Tong X, et al: Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J Clin Oncol 20:2302-2309, 2002
27. Schoch C, Schnittger S, Klaus M, et al: AML with 11q23/MLL abnormalities as defined by the WHO classification: Incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 102:2395-2402, 2003
28. Nguyen S, Leblanc T, Fenaux P, et al: A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): A survey of 161 cases from the French AML Intergroup. Blood 99:3517-3523, 2002
29. Schlenk RF, Benner A, Krauter J, et al: Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: A survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 22:3741-3750, 2004
30. Delaunay J, Vey N, Leblanc T, et al: Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): A survey of 110 cases from the French AML Intergroup. Blood 102:462-469, 2003
31. Blum W, Mrozek K, Ruppert AS, et al: Adult de novo acute myeloid leukemia with t(6;11)(q27; q23): Results from Cancer and Leukemia Group B Study 8461 and review of the literature. Cancer 101:1420-1427, 2004
32. Harbott J, Mancini M, Verellen-Dumoulin C, et al: Hematological malignancies with a deletion of 11q23: Cytogenetic and clinical aspects - European 11q23 Workshop participants. Leukemia 12:823-827, 1998
33. Archimbaud E, Charrin C, Magaud JP, et al: Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly or MLL gene rearrangement compared to cases with unbalanced 11q23 anomaly: Confirmation of the existence of different entities with 11q23 breakpoint. Leukemia 12:25-33, 1998
34. Dohner K, Schlenk RF, Habdank M, et al: Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 106:3740-3746, 2005
35. Schlenk RF, Dohner K, Krauter J, et al: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1909-1918, 2008
36. Schmid C, Schleuning M, Schwerdtfeger R, et al: Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 108:1092-1099, 2006
37. Bunjes D, Buchmann I, Duncker C, et al: Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: Results of a phase I-II study. Blood 98:565-572, 2001